Search results for "high dose"

showing 10 items of 36 documents

Minimum effective dose for antidepressants - an obligatory requirement for antidepressant drug evaluation?

1996

Extensive clinical trials are required for registration and approval of new antidepressants in most countries including the requirement that a minimal effective dose should be determined. The rationale for this requirement is to avoid the use of unnecessarily high doses. The implication is that for every antidepressant, a dose exists that serves as a threshold, below which all doses are not effective or are clearly less effective in treating a major depressive episode. Dose titration and fixed dose studies are used to determine the minimal effective dose, but both strategies have limitations and often do not allow definite establishment of a clear-cut minimal effective dose. The effort of e…

Drugmedicine.medical_specialtymedia_common.quotation_subjectComorbidityPharmacologyPharmacokineticsmedicineHigh dosesHumansEthics MedicalPharmacology (medical)Intensive care medicineMajor depressive episodemedia_commonClinical Trials as TopicDepressive DisorderDose-Response Relationship Drugbusiness.industryConfounding Factors EpidemiologicEffective dose (pharmacology)Antidepressive AgentsClinical trialPsychiatry and Mental healthSample size determinationAntidepressantmedicine.symptombusinessInternational Clinical Psychopharmacology
researchProduct

Myelography: current status and post-marketing experience with iotrolan

1995

There are three imaging modalities for the diagnosis of spinal diseases: magnetic resonance imaging (MRI), computed tomography (CT) and myelography. The choice of modality is influenced by factors including diagnostic accuracy cost, radiation dose and invasiveness. For many indications, MRI has advantages over CT and myelography and is the modality of choice, and there is likely to be a trend away from myelographic examinations. In cases where myelography is indicated, it is of prime importance to reduce the frequency and severity of adverse events. During phase III and IV trials, involving over 2000 patients, general and neural tolerance of iotrolan was shown to be significantly better tha…

Iotrolanmedicine.medical_specialtymedicine.diagnostic_testbusiness.industryMagnetic resonance imagingInterventional radiologyGeneral MedicineIopamidolchemistry.chemical_compoundchemistryMetrizamideHigh dosesmedicineRadiology Nuclear Medicine and imagingRadiologyNuclear medicinebusinessMyelographymedicine.drugNeuroradiologyEuropean Radiology
researchProduct

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

2020

Abstract Purpose To evaluate the antiproliferative activity and safety of nonconventional high doses of somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) with radiological disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on a previous treatment. Methods A retrospective analysis of prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion criteria were: well-differentiated G1 or G2 GEP-NET, progressive disease on a previous treatment, and subsequent treatment with HD-SSA (either by increased administered dose [dose intensity] or…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryOctreotideNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyhigh dose80 and overMedicineProspective StudiesProspective cohort studyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogs; Adult; Aged; Aged 80 and over; Female; Follow-Up Studies; Hormones; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Prospective Studies; Retrospective Studies; Somatostatin; Cell DifferentiationAged 80 and overLiver NeoplasmsCell DifferentiationMiddle Agednonconventional dosePrognosissomatostatin analogsNeuroendocrine TumorsResponse Evaluation Criteria in Solid TumorsFemalelanreotideSomatostatinmedicine.drugAdultmedicine.medical_specialtyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogsInternal medicinenonconventional dosesHumansAdverse effectAgedRetrospective Studiesbusiness.industryBiochemistry (medical)medicine.diseaseHormonesClinical trialNETEndocrinologychemistrybusinessProgressive diseaseoctreotideFollow-Up Studies
researchProduct

Role of acute social stress in the rewarding effects of MDMA in adolescent mice

2021

Drug use among adolescents is a serious problem in our society, as some individuals develop dependence and addiction. MDMA/Esctasy is one of the most typically used substances by this age group. It is well known that environmental factors can alter the rewarding properties of drugs and the propensity to drug-related disorders. In this sense, exposure to social stress induces long-term effects in mice, enhancing the rewarding effects of MDMA in the conditioned place preference (CPP) paradigm. On the other hand, previous research has not provided conclusive results regarding the short-term effects of social defeat on MDMA reward in adolescent animals, probably due to the use of very low or ve…

MaleN-Methyl-34-methylenedioxyamphetaminemedia_common.quotation_subjectConditioning ClassicalSocial DefeatSocial defeatMice03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineRewardmental disordersHigh dosesAnimalsMedicine030304 developmental biologymedia_commonSocial stress0303 health sciencesBehavior Animalbusiness.industryAddictionAge FactorsMDMAConditioned place preferenceDisease Models AnimalCentral Nervous System StimulantsbusinessStress Psychologicalpsychological phenomena and processes030217 neurology & neurosurgerymedicine.drugClinical psychologyBehavioural Brain Research
researchProduct

The use of high doses of oxycodone in an acute palliative care unit.

2010

A retrospective study of patients who were prescribed controlled-release oxycodone (CRO) in a period of 3 years (2006-2008) was performed. A total of 212 patients were prescribed at discharge CRO for background analgesia; 129, 43, and 40 patients were prescribed doses of oxycodone of less than 120 mg/day (group L), 120 to 240 mg/day (group M), and more than 240 mg/day (group L), respectively. No differences in gender, primary diagnosis, and pain mechanisms were found, but doses were significantly lower in older patients (P < .0005). At discharge, adverse effects were mild and only a minority of patients were switched to other opioids. This study demonstrated that CRO administered in lar…

MalePalliative carePainoxycodoneSettore MED/42 - Igiene Generale E ApplicataNeoplasmsmedicineHigh dosesHumansAdverse effectAgedRetrospective StudiesDose-Response Relationship Drugbusiness.industryPalliative CareAge FactorsRetrospective cohort studyGeneral MedicineMiddle Agedacute palliative care unitoxycodone; acute palliative care unit; trial clinicoAnalgesics OpioidDose–response relationshipDelayed-Action PreparationsAnesthesiaAcute DiseaseMorphineFemaletrial clinicobusinessCancer painOxycodonemedicine.drug
researchProduct

Effects of risperidone on conditioned avoidance responding in male mice

1998

The effects of risperidone (0.1, 0.5 and 1 mg/kg) on active avoidance behaviour of BALB/C mice were explored in three acquisition sessions and in one subsequent performance session. In the acquisition phase, risperidone-treated animals showed a decrease in avoidances and in crossings in the adaptation period and in the intertrial intervals (ITIs), and an increase in non-responses; intermediate and high doses also decreased defecation. In the performance phase, 0.5 and 1 mg/kg risperidone decreased avoidance responses, crossings in the adaptation period and ITI crossing, which also decreased with 0.1 mg/kg. Moreover, 0.5 mg/kg of risperidone increased escape responses and 1 mg/kg increased n…

MalePharmacologyMice Inbred BALB Cmedicine.medical_specialtyRisperidonebusiness.industryMale miceRisperidoneMicePsychiatry and Mental healthEndocrinologyAvoidance behaviourInternal medicineAvoidance LearningmedicineHigh dosesDecreased defecationAnimalsDefecationbusinessPsychomotor PerformanceAntipsychotic Agentsmedicine.drugBehavioural Pharmacology
researchProduct

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

2008

INTRODUCTION: The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 microg of TD fentanyl, reporting adequate pain and symptom control. MATERIALS, METHODS, AND RESULTS: Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl-BUP ratio of 0.6:0.8 and an oral morphine-BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakth…

Maletransdermal buprenorphinePainAdministration CutaneousFentanylNeoplasmsHigh dosesMedicineHumansSymptom controlProspective StudiesOral morphineAgedDose-Response Relationship Drugbusiness.industryMiddle AgedEquianalgesicBuprenorphineAnalgesics OpioidFentanylOncologyPatient SatisfactionAnesthesiaFemaleTransdermal Buprenorphinehigh doses of opioidsbusinessCancer painmedicine.drugSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

Statistical methods for determining components non-liniarities, from thermoluminescent devices

2016

Thermoluminescent (TLD) dosimeters enjoy wide usage due to low cost and simplicity of use. They have however large errors at high doses in mixed-radiation fields, where non-linear effects occur. Algorithms based on the Akaike criterion [1] are presented for determining the maximal (physically meaningful) polynomial order with which the non-linearities are modeled. This depends on the number of points existing on a curve and on the points' errors.

Mathematical optimizationmedia_common.quotation_subjectPhysics::Medical PhysicsPolynomial order02 engineering and technology021001 nanoscience & nanotechnology01 natural sciencesThermoluminescence0103 physical sciencesAkaike criterionHigh dosesThermoluminescent dosimeterSimplicity010306 general physics0210 nano-technologyAlgorithmmedia_commonMathematics2016 IEEE 22nd International Symposium for Design and Technology in Electronic Packaging (SIITME)
researchProduct

A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis

2002

Objective - To investigate the efficacy of two different high doses of intravenous methylprednisolone (IVMP) during Multiple Sclerosis (MS) relapses. Background - Transcranial Magnetic Stimulation (TMS) is the most sensitive neurophysiological ascertainment to quantify motor disability, to follow the recovery from an MS relapse, and to detect the response to treatment. Design and method - Twenty-four clinically definite relapsing - remitting MS patients presenting a relapse were randomly assigned to a treatment for 5 days with IVMP 1 or 2 g/day. The response to treatment of each patient was evaluated through Expanded Disability Status Scale (EDSS), Medical Research Council (MRC) score, and …

Neuroscience (all)High dose methylprednisoloneMultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)Randomized trialTranscranial magnetic stimulation
researchProduct

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT…

2021

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry …

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinClinical InvestigationsImproved survival610 Medicine & healthBrain Neoplasms/drug therapyCentral Nervous System NeoplasmsHigh dose chemotherapychemistry.chemical_compoundCarboplatin/therapeutic useInternal medicinemedicineHigh-dose chemotherapyHumansNeuroectodermal Tumors Primitive1306 Cancer ResearchProspective StudiesChildOutcomeEtoposideRetrospective StudiesChemotherapyddc:618business.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfantInduction ChemotherapyNeoplasms Germ Cell and EmbryonalCarboplatinETMRRadiation therapyClinical trialClinical trial2728 Neurology (clinical)Oncologychemistry10036 Medical ClinicChild Preschool2730 OncologyNeurology (clinical)Antineoplastic Combined Chemotherapy Protocols/therapeutic usebusinessCarboplatin/etoposideNeoplasms Germ Cell and Embryonal/drug therapy
researchProduct